Actively Recruiting
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Led by University of California, Los Angeles · Updated on 2026-03-13
75
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of California, Los Angeles
Lead Sponsor
B
Bausch & Lomb Incorporated
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate how glaucoma patients respond to treatment with Xiidra (Lifitegrast ophthalmic solution) 5%, an FDA-approved eye drop used for ocular surface discomfort. The study focuses on discomfort caused partly by the use of topical glaucoma antihypertensive medications. The purpose is to better understand the effects of Xiidra when prescribed as part of standard care for these patients. Participants will use Xiidra eye drops in both eyes for a period of 12 weeks. The treatment is administered topically and is part of the patient's usual glaucoma care. The study observes changes in symptoms related to ocular surface discomfort over this 12-week treatment period. During the study, participants will be assessed at baseline and at weeks 2, 6, and 12. Researchers will measure changes in corneal fluorescein staining scores, eye dryness scores, and ocular surface disease index (OSDI) questionnaire scores to evaluate the treatment's impact. These assessments help monitor how symptoms evolve with treatment, and participants’ safety and response will be observed throughout the study duration.
CONDITIONS
Brief Title
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
You will not qualify if you...
- History of glaucoma filtration surgery or ocular surface surgery such as pterygium or conjunctivoplasty
- Current use of topical cyclosporine
- Current use of topical steroids
- Incisional ocular surgery within the past 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants use Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eyes as part of their standard care to address ocular surface discomfort.
Visits at baseline, and at weeks 2, 6, and 12
Trial Site Locations
Total: 1 location
1
Doheny Eye Center UCLA
Fountain Valley, California, United States, 92708
Actively Recruiting
Research Team
B
Benjamin B Bert, MD
M
Mayra Raygoza
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here